Is it leukaemia? Haematological disorders in paediatric patients with Down syndrome — case report and literature review
, 1, 1, 2
Abstract
Introduction: Down syndrome (DS) is the most common chromosomal aberration. DS is characterized
by a higher incidence of many disorders, including those involving the haematopoietic system. The risk
of developing acute myeloid leukaemia is up to 150 times higher in this group. Also, characteristic is the
presence of transient abnormal myelopoiesis (TAM), which can precede the development of malignancy.
These phenomena are primarily associated with mutation of the GATA1 gene, cohesin complex and signalling
pathways genes, as well as overactivity of foetal liver stromal cells and intensification of inflammation,
stimulating the expansion of blastic cells.
Case report: A 15-month-old patient diagnosed with DS was admitted to the Clinic for diagnosis of neutropenia
and thrombocytopenia. The myelogram showed no features of proliferative disease; however, TAM
was suspected based on the bone marrow biopsy result. Six months later, based on the evaluation of the
myelogram and immunophenotype of tumour cells, myeloid leukaemia (ML-DS) with megakaryoblastic
differentiation was diagnosed. Genetic testing revealed a mutation in the GATA1 gene. The girl was qualified
for treatment according to the AML-BFM 2019-ML-DS Protocol. The treatment was carried out as planned
and the patient has achieved remission.
Conclusions: The pathogenesis of myelopoietic disorders in children with DS is mainly due to a cascade
of mutations and genetic abnormalities. For this reason, DS patients must have appropriate molecular
testing and regular haematologic follow-up to closely observe the evolution of myelopoietic disorders.
Keywords: leukaemiaDown syndromechildrenhaematologygenetics
References
- Antonarakis SE, Skotko BG, Rafii MS, et al. Down syndrome. Nat Rev Dis Primers. 2020; 6(1): 9.
- Baksh RA, Pape SE, Chan LiF, et al. GO-DS21 Consortium. Multiple morbidity across the lifespan in people with Down syndrome or intellectual disabilities: a population-based cohort study using electronic health records. Lancet Public Health. 2023; 8(6): e453–e462.
- Shimada A. Profile of down syndrome–associated malignancies: Epidemiology, clinical features and therapeutic aspects. Pediatric Hematology Oncology Journal. 2021; 6(2): 63–72.
- Triarico S, Trombatore G, Capozza MA, et al. Hematological disorders in children with Down syndrome. Expert Rev Hematol. 2022; 15(2): 127–135.
- Kosmidou A, Tragiannidis A, Gavriilaki E. Myeloid Leukemia of Down Syndrome. Cancers (Basel). 2023; 15(13).
- de Castro CP, Cadefau M, Cuartero S. The Mutational Landscape of Myeloid Leukaemia in Down Syndrome. Cancers (Basel). 2021; 13(16).
- Choi JK. Hematopoietic disorders in Down syndrome. Int J Clin Exp Pathol. 2008; 1(5): 387–395.
- Schmidt MP, Colita A, Ivanov AV, et al. Outcomes of patients with Down syndrome and acute leukemia: A retrospective observational study. Medicine (Baltimore). 2021; 100(40): e27459.
- Gupte A, Al-Antary ET, Edwards H, et al. The paradox of Myeloid Leukemia associated with Down syndrome. Biochem Pharmacol. 2022; 201: 115046.
- Goemans BF, Noort S, Blink M, et al. Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia. Leukemia. 2021; 35(8): 2403–2406.
- Boucher AC, Caldwell KJ, Crispino JD, et al. Clinical and biological aspects of myeloid leukemia in Down syndrome. Leukemia. 2021; 35(12): 3352–3360.
- Baloda V, Subramanian P, Badrinath Y, et al. Transient abnormal myelopoiesis: A case series and review of the literature. Pediatric Hematology Oncology Journal. 2017; 2(1): 14–18.
- Bhatnagar N, Nizery L, Tunstall O, et al. Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr Hematol Malig Rep. 2016; 11(5): 333–341.
- Li J, Kalev-Zylinska ML. Advances in molecular characterization of myeloid proliferations associated with Down syndrome. Front Genet. 2022; 13: 891214.
- Barwe SP, Sebastian A, Sidhu I, et al. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of and Mutations in Induced Pluripotent Stem Cells with Trisomy 21. Cells. 2022; 11(4).
- Arkoun B, Robert E, Boudia F, et al. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model. J Clin Invest. 2022; 132(14).
- Labuhn M, Perkins K, Matzk S, et al. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell. 2019; 36(2): 123–138.e10.
- Uffmann M, Rasche M, Zimmermann M, et al. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood. 2017; 129(25): 3314–3321.
- Raghuram N, Hasegawa D, Nakashima K, et al. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Adv. 2023; 7(21): 6532–6539.